Global Artificial Retina Implant Market Research Report Information by Product, by Application, and by End User and by Region

Description

List of Tables

Global Artificial Retina Implant Market Research Report Information by Product (Enzymes, Pharma Products, Bulk Chemicals, and Others), by Application (Bioengineering, Genomics, Vaccine Development, Drug Discovery, Fisheries, Aquaculture, Biofuels, Water Treatment Services, and Others), and by End User (Hospitals, Pharmaceutical Companies, Biotechnology Companies, and Others) and by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2032

Market Synopsis

The market for artificial retinal implants was estimated to be worth USD 1.51 billion in 2025. The Artificial Retina Implant market is expected to expand at a compound annual growth rate (CAGR) of 21.22% between 2026 and 2032, from USD 1.92 billion in 2026 to USD 7.04 billion.

The rising prevalence of retinitis pigmentosa and age-related macular degeneration (AMD), as well as the rise in the number of startups offering artificial retina implants, are the main reasons propelling the expansion of the global market.

In September 2021, Bionic Vision Technologies, a well-known brand in artificial retina technology, announced a significant collaboration with Cirtec Medical, a top medical technology business with its headquarters located in the US. The collaborative effort will facilitate the design process and allow for cooperative production of the next generation of bionic eyes. With the resources and expertise base of Cirtec Medical at its disposal, Bionic Vision Technologies hopes to advance its cutting-edge bionic eye technology and provide improved vision solutions for those with visual impairments.

Insights on Market Segments

The Artificial Retina Market is divided into three segments based on product type: suprachoroidal implants, subretinal implants, and epiretinal implants.

The artificial retina market has been divided into two segments based on application: retinitis pigmentosa and age-related macular degeneration (AMD).

Regional Perspectives

The market is divided into four regions by the study: North America, Europe, Asia-Pacific, and the Rest of the World. With a market share of more than 50.12% in 2025, the artificial retina implant market in North America held the biggest share due to the rising prevalence of age-related macular degeneration (AMD) and the availability of FDA-approved implant products. For example, Argus II is a product that the FDA has approved and is accessible in the United States.

The artificial retina implant market in Europe is expected to increase significantly between 2025 and 2026, primarily due to the frequent strategic alliances formed by industry participants to meet customer demand. For example, Pixium Vision (France) revealed in July 2022 that the first patient in the Netherlands had a successful implantation in the Prima System European pivotal trial PRIMAvera. Since then, Pixium Vision has created more clinical locations and implanted patients in the UK and Germany.

The Asia-Pacific artificial retina implant market is expected to develop at the quickest rate during the forecast period due to the region's growing geriatric population, which is expected to significantly contribute to the industry's growth. For example, the Asia-Pacific Report on Population Ageing 2022 estimates that 670 million or more persons in Asia-Pacific were 60 years of age or older in 2022. In the Asia-Pacific region, the population is predicted to treble to almost 1.3 billion by 2050.

Key Players

Bionic Vision Technologies (US), PIXIUM VISION (France), Optobionics (US), Labtician Ophthalmics, Inc. (Canada), Vivani Medical Inc. (US), iBIONICS (Canada), LambdaVision, Inc. (US), AXORUS (France), Sensor-Tech Lab (Russia), and Nanovision (US) are some of the prominent companies in the artificial retina implant market.

Product Code: MRFR/MED/2095-CR

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE AND ASSUMPTIONS
2.5 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW
3.2 DATA FLOW
- 3.2.1 DATA MINING PROCESS
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
- 3.4.1 SECONDARY RESEARCH DATA FLOW:
3.5 PRIMARY RESEARCH:
- 3.5.1 PRIMARY RESEARCH DATA FLOW:
- 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
- 3.6.1 REVENUE ANALYSIS APPROACH
3.7 DATA FORECASTING
- 3.7.1 DATA FORECASTING TECHNIQUE
3.8 DATA MODELING
- 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
- 3.8.2 DATA MODELING:

4 MARKET DYNAMICS

4.1 INTRODUCTION
4.2 DRIVERS
- 4.2.1 INCREASING INCIDENCES OF AGE-RELATED MACULAR DEGENERATION (AMD) AND RETINITIS PIGMENTOSA
- 4.2.2 GROWING NUMBER OF STARTUPS ASSOCIATED WITH ARTIFICIAL RETINA IMPLANT
4.3 RESTRAINTS
- 4.3.1 HIGH COST ASSOCIATED WITH ARTIFICIAL RETINA IMPLANT PROCEDURES
4.4 OPPORTUNITY
- 4.4.1 INCREASING FUNDING & INVESTMENT FOR ARTIFICIAL RETINA IMPLANT

5 MARKET FACTOR ANALYSIS

5.1 PORTER'S FIVE FORCES MODEL
- 5.1.1 THREAT OF NEW ENTRANTS
- 5.1.2 BARGAINING POWER OF SUPPLIERS
- 5.1.3 THREAT OF SUBSTITUTES
- 5.1.4 BARGAINING POWER OF BUYERS
- 5.1.5 INTENSITY OF RIVALRY
5.2 KEY PLAYERS DEVELOPING BRAIN IMPLANTS TO TREAT VISION LOSS

6 GLOBAL ARTIFICIAL RETINA IMPLANT MARKET, BY PRODUCT TYPE

6.1 OVERVIEW
6.2. EPIRETINAL IMPLANTS
6.3. SUBRETINAL IMPLANTS
6.4. SUPRACHOROIDAL IMPLANTS

7 GLOBAL ARTIFICIAL RETINA IMPLANT MARKET, BY APPLICATION

7.1 OVERVIEW
7.2. AGE-RELATED MACULAR DEGENERATION (AMD)
7.3. RETINITIS PIGMENTOSA

8 GLOBAL ARTIFICIAL RETINA IMPLANT MARKET, BY REGION

8.1 OVERVIEW

9 COMPETITIVE LANDSCAPE

9.1 INTRODUCTION
9.2 COMPETITOR DASHBOARD
9.3 PUBLIC PLAYERS STOCK SUMMARY
9.4 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
9.5 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 9.5.1 PARTNERSHIP
- 9.5.2 EXPANSION
- 9.5.3 MERGER

10 COMPANY PROFILES

10.1 VIVANI MEDICAL INC.
- 10.1.1 COMPANY OVERVIEW
- 10.1.2 FINANCIAL OVERVIEW
- 10.1.3 PRODUCTS OFFERED
- 10.1.4 KEY DEVELOPMENTS
- 10.1.5 SWOT ANALYSIS
- 10.1.6 KEY STRATEGIES
10.2 IBIONICS
- 10.2.1 COMPANY OVERVIEW
- 10.2.2 FINANCIAL OVERVIEW
- 10.2.3 PRODUCTS OFFERED
- 10.2.4 KEY DEVELOPMENTS
- 10.2.5 SWOT ANALYSIS
- 10.2.6 KEY STRATEGY
10.3 NANOVISION BIOSCIENCES
- 10.3.1 COMPANY OVERVIEW
- 10.3.2 FINANCIAL OVERVIEW
- 10.3.3 PRODUCTS OFFERED
- 10.3.4 KEY DEVELOPMENTS
- 10.3.5 KEY STRATEGY
10.4 SENSOR-TECH LAB
- 10.4.1 COMPANY OVERVIEW
- 10.4.2 FINANCIAL OVERVIEW
- 10.4.3 PRODUCTS OFFERED
- 10.4.4 KEY DEVELOPMENTS
- 10.4.5 KEY STRATEGY
10.5 LABTICIAN OPHTHALMICS, INC
- 10.5.1 COMPANY OVERVIEW
- 10.5.2 FINANCIAL OVERVIEW
- 10.5.3 PRODUCTS OFFERED
- 10.5.4 KEY DEVELOPMENTS
- 10.5.5 SWOT ANALYSIS
- 10.5.6 KEY STRATEGIES
10.6 OPTOBIONICS
- 10.6.1 COMPANY OVERVIEW
- 10.6.2 FINANCIAL OVERVIEW
- 10.6.3 PRODUCTS OFFERED
- 10.6.4 KEY DEVELOPMENTS
- 10.6.5 KEY STRATEGIES
10.7 LAMBDAVISION, INC.
- 10.7.1 COMPANY OVERVIEW
- 10.7.2 FINANCIAL OVERVIEW
- 10.7.3 PRODUCTS OFFERED
- 10.7.4 KEY DEVELOPMENTS
- 10.7.5 SWOT ANALYSIS
- 10.7.6 KEY STRATEGIES
10.8 BIONIC VISION TECHNOLOGIES
- 10.8.1 COMPANY OVERVIEW
- 10.8.2 FINANCIAL OVERVIEW
- 10.8.3 PRODUCTS/SERVICES OFFERED
- 10.8.4 KEY DEVELOPMENTS
- 10.8.5 KEY STRATEGIES
10.9 PIXIUM VISION
- 10.9.1 COMPANY OVERVIEW
- 10.9.2 FINANCIAL OVERVIEW
- 10.9.3 PRODUCTS OFFERED
- 10.9.4 KEY DEVELOPMENTS
- 10.9.5 SWOT ANALYSIS
- 10.9.6 KEY STRATEGIES
10.10 AXORUS
- 10.10.1 COMPANY OVERVIEW
- 10.10.2 FINANCIAL OVERVIEW
- 10.10.3 PRODUCTS OFFERED
- 10.10.4 KEY DEVELOPMENTS
- 10.10.5 KEY STRATEGIES
10.11 DATA CITATIONS